Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

ClinicalTrials.gov ID: NCT02207244

Public ClinicalTrials.gov record NCT02207244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment

Study identification

NCT ID
NCT02207244
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
992 participants

Conditions and interventions

Conditions

Interventions

  • Guselkumab 100 mg Drug
  • Placebo for guselkumab Drug
  • Adalimumab Drug
  • Placebo for adalimumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2, 2014
Primary completion
Sep 30, 2015
Completion
Jun 30, 2020
Last update posted
Jul 21, 2021

2014 – 2020

United States locations

U.S. sites
32
U.S. states
21
U.S. cities
32
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Bakersfield California
Not listed Los Angeles California
Not listed San Diego California
Not listed Santa Monica California
Not listed Aurora Colorado
Not listed Coral Gables Florida
Not listed Tampa Florida
Not listed Newnan Georgia
Not listed Sandy Springs Georgia
Not listed Chicago Illinois
Not listed Rolling Meadows Illinois
Not listed Skokie Illinois
Not listed Indianapolis Indiana
Not listed Plainfield Indiana
Not listed Louisville Kentucky
Not listed Andover Massachusetts
Not listed Fort Gratiot Michigan
Not listed Troy Michigan
Not listed St Louis Missouri
Not listed Albuquerque New Mexico
Not listed New York New York
Not listed Gahanna Ohio
Not listed Norman Oklahoma
Not listed Portland Oregon
Not listed Pittsburgh Pennsylvania
Not listed Johnston Rhode Island
Not listed Arlington Texas
Not listed Houston Texas
Not listed Salt Lake City Utah
Not listed Seattle Washington
Not listed Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02207244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2021 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02207244 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →